SCHEMBL4244202

SCHEMBL4244202

O=c1c2cccc(O)c2nc(-c2ccc(F)cc2)n1NCc1ccc(Br)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
TNKS O95271 2/20 0.42
PARP1 P09874 2/20 0.42
TNKS2 Q9H2K2 2/20 0.42
EGFR P00533 1/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
CES2 O00748 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP3A4 P08684 1/20 0.37
F2RL1 P55085 1/20 0.37
LMNA P02545 3/20 0.37
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4239826 0.90 SMN1; SMN2 (0.57) SMN1; SMN2MAPTNPSR1TNKSPARP1
SCHEMBL4241365 0.89 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1TNKSTNKS2
SCHEMBL4242256 0.86 MEN1 (0.48) SMN1; SMN2MAPTNPSR1TNKSTNKS2
SCHEMBL4236185 0.83 SMN1; SMN2 (0.67) SMN1; SMN2MAPTNPSR1EGFRMEN1
SCHEMBL4199192 0.81 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1EGFRMEN1
SCHEMBL4239901 0.80 SMN1; SMN2 (0.54) SMN1; SMN2MAPTNPSR1EGFRMEN1
SCHEMBL4233197 0.78 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1TNKSTNKS2
SCHEMBL4735977 0.77 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1PARP1EGFR
SCHEMBL4196795 0.77 SMN1; SMN2 (0.46) SMN1; SMN2MAPTNPSR1EGFRMEN1
SCHEMBL4244207 0.77 MAPT (0.62) SMN1; SMN2MAPTNPSR1EGFRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 SMN1; SMN2 4767/4885MAPT 4430/4885NPSR1 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.